Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease-free survival · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
OS at 2 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Disease-free survival · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
OS at 2 years · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Participants requiring dose reduction · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher participants requiring dose reduction compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher anaemia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Febrile neutropenia (grade III/IV) · early triple‐negative breast cancer
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · early triple‐negative breast cancer
1 finding from 1 review
Quality of life · early triple‐negative breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Eradication proportion · participants with Helicobacter pylori infection
The intervention showed no clear difference in eradication proportion (moderate certainty).
1 finding from 1 review
Intervention not reported
Geographic region · participants with Helicobacter pylori infection
The intervention showed no clear difference in geographic region (low certainty).
1 finding from 1 review
Intervention not reported
Publication date · participants with Helicobacter pylori infection
The intervention showed no clear difference in publication date (moderate certainty).
1 finding from 1 review
Intervention not reported
STT length · participants with Helicobacter pylori infection
The intervention showed no clear difference in STT length (high certainty).
1 finding from 1 review
Intervention not reported
Bacterial antibiotic resistance · participants with Helicobacter pylori infection
It is very uncertain whether the intervention changes bacterial antibiotic resistance (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events rate · participants with Helicobacter pylori infection
The intervention showed no clear difference in adverse events rate (high certainty).
1 finding from 1 review